Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

This phase 2 study was conducted to prospectively evaluate how clinical and biological factors correlate with outcome in patients with treatment-naive (TN) and relapsed (R) chronic lymphocytic leukemia (CLL) treated with lenalidomide and rituximab. Oral lenalidomide 10 mg was administered daily star...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: Strati, Paolo, Takahashi, Koichi, Peterson, Christine B., Keating, Michael J., Thompson, Philip A., Daver, Naval G., Jain, Nitin, Burger, Jan A., Estrov, Zeev, O'Brien, Susan M., Kantarjian, Hagop M., Wierda, William G., Futreal, P. Andrew, Ferrajoli, Alessandra
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2019
Teme:
Lymphoid Neoplasia
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517659/
https://ncbi.nlm.nih.gov/pubmed/31076409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019031336
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki